JPMorgan Chase & Co. Boosts Chemours (NYSE:CC) Price Target to $22.00

Chemours (NYSE:CC) had its target price increased by research analysts at JPMorgan Chase & Co. from $17.00 to $22.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the specialty chemicals company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 2.32% from the stock’s previous close.

A number of other research firms have also weighed in on CC. Alembic Global Advisors reissued an “overweight” rating and issued a $30.00 price objective on shares of Chemours in a research report on Wednesday, May 13th. UBS Group increased their price objective on shares of Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Friday, April 24th. Mizuho set a $30.00 price objective on shares of Chemours in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their price objective on shares of Chemours from $26.00 to $29.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.55.

Chemours Price Performance

Shares of NYSE CC traded down $0.77 during mid-day trading on Thursday, hitting $21.50. 2,537,990 shares of the company’s stock traded hands, compared to its average volume of 3,335,669. The company’s 50-day moving average is $22.29 and its two-hundred day moving average is $17.25. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. The company has a market capitalization of $3.23 billion, a P/E ratio of -8.13 and a beta of 1.47. Chemours has a 1 year low of $9.13 and a 1 year high of $28.67.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.10. The firm had revenue of $1.38 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The business’s revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.13 EPS. On average, equities analysts anticipate that Chemours will post 1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Chemours

Hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd purchased a new position in Chemours in the third quarter worth $2,124,000. WINTON GROUP Ltd grew its holdings in Chemours by 103.5% in the third quarter. WINTON GROUP Ltd now owns 114,100 shares of the specialty chemicals company’s stock worth $1,807,000 after purchasing an additional 58,039 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in Chemours in the third quarter worth $1,925,000. SG Americas Securities LLC grew its holdings in Chemours by 478.4% in the fourth quarter. SG Americas Securities LLC now owns 236,236 shares of the specialty chemicals company’s stock worth $2,785,000 after purchasing an additional 195,393 shares during the last quarter. Finally, Wolf Hill Capital Management LP purchased a new position in Chemours in the third quarter worth $17,025,000. 76.26% of the stock is currently owned by institutional investors.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Zacks Research sharply reduced Chemours’ Q2 2026 EPS estimate to $0.33 from $0.60, signaling weaker near-term earnings expectations.
• Negative Sentiment: The firm also cut FY2026 EPS to $0.90 from $1.06 and lowered FY2027 EPS slightly, reinforcing concerns about the company’s earnings trajectory.
• Negative Sentiment: Additional downgrades to Q1 2027, Q2 2027, Q3 2026, and Q4 2026 earnings estimates suggest analysts see continued margin or demand pressure in the next few quarters.
• Neutral Sentiment: Zacks Research kept its Hold rating on Chemours, indicating analysts are not turning bullish despite some longer-term estimate increases for 2027 and 2028.
• Positive Sentiment: Some longer-dated estimates were nudged higher, including Q4 2027 and Q3 2027 EPS, which suggests analysts still see a possible earnings recovery over time.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.